Journal
SCIENCE
Volume 337, Issue 6100, Pages 1343-1348Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1222908
Keywords
-
Categories
Funding
- National Institute of General Medical Sciences (NIGMS) Protein Structure Initiative [U54 GM094586]
- NIH through the National Center for Research Resources' P41 program [RR017573]
- Area of Excellence Scheme of the University Grants Committee, Hong Kong [AoE/M-12/06]
- Achievement Rewards for College Scientists Foundation
- NIH Molecular Evolution Training Program [GM080209]
- Danish Council for Independent Research, Natural Sciences
- Skaggs Institute
- DOE Office of Biological and Environmental Research
- NIH, National Center for Research Resources, Biomedical Technology Program [P41RR001209]
- NIGMS [Y1-GM-1104]
- National Cancer Institute [Y1-CO-1020]
- DOE, Basic Energy Sciences, Office of Science [DE-AC02-06CH11357]
- Office of Science, Office of Basic Energy Sciences, of the DOE [DE-AC02-05CH11231]
Ask authors/readers for more resources
Identification of broadly neutralizing antibodies against influenza A viruses has raised hopes for the development of monoclonal antibody-based immunotherapy and universal vaccines for influenza. However, a substantial part of the annual flu burden is caused by two cocirculating, antigenically distinct lineages of influenza B viruses. Here, we report human monoclonal antibodies, CR8033, CR8071, and CR9114, that protect mice against lethal challenge from both lineages. Antibodies CR8033 and CR8071 recognize distinct conserved epitopes in the head region of the influenza B hemagglutinin (HA), whereas CR9114 binds a conserved epitope in the HA stem and protects against lethal challenge with influenza A and B viruses. These antibodies may inform on development of monoclonal antibody-based treatments and a universal flu vaccine for all influenza A and B viruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
